Camlin Fine Q1FY27: consolidated loss widens to ₹33.6 Cr as EBITDA margin falls to 3.4%

Camlin Fine Sciences' consolidated (primary) Q1 FY27 loss widened to ₹33.62 Cr from ₹10.68 Cr a year ago — reported PAT down roughly 215% YoY; adjusted for this quarter's ₹11.11 Cr exceptional charge, the underlying loss was still up ~111% YoY to ₹22.51 Cr. Standalone lost a smaller ₹12.31 Cr, more than 2x divergence from consolidated — the gap is mostly subsidiaries' operating losses, the exceptional charge (booked only at the consolidated level) and a ₹1.83 Cr discontinued-operations loss that doesn't touch the standalone P&L. Consolidated revenue from operations was ₹519.88 Cr, up 22.7% YoY (against our tracked year-ago base of ₹423.55 Cr) and 22.4% QoQ against this filing's own recast Q4 FY26 column of ₹424.81 Cr. No management press release accompanied this filing, and there is no formal quarterly Street consensus available for Camlin Fine, so vs-Street reads unknown — Trendlyne's two-analyst FY27 consensus pegs full-year revenue near ₹2,361 Cr and EPS at ₹7.65, both now resting on a much bigger back-half recovery after this loss-making Q1.

The loss was a margin story, not a revenue miss. Consolidated operating EBITDA (segment results before exceptional items) fell to ₹17.64 Cr — a 3.39% margin — from ₹21.19 Cr (4.99%) in Q4 FY26 and ₹20.29 Cr (4.98%) in Q1 FY26, even as revenue grew double digits both sequentially and YoY, meaning input and employee costs outpaced the topline. The ₹11.11 Cr exceptional charge splits into a ₹10.88 Cr shortfall on the insurance claim settlement for the February 2026 fire at CFS Do Brasil's blending unit (Note 7) plus ₹0.23 Cr unallocated — a real cash item, not a paper adjustment. By segment: Specialty Ingredients (the largest) grew revenue 36.7% YoY to ₹401.32 Cr but its segment result fell 15.1% YoY to ₹25.47 Cr; Aroma revenue rose 36.6% YoY to ₹77.41 Cr — consistent with management's guided vanillin volume/realisation pickup — yet stayed loss-making at -₹3.38 Cr, though narrower than Q4's -₹8.80 Cr; Performance Chemicals & Others swung from a ₹3.65 Cr profit in Q4 to a -₹4.44 Cr loss, still better than the -₹7.65 Cr loss a year ago.

The stock went into the print at ₹126, down 0.1% over the past month of trading.

For context: revenue is at a 6-quarter high.

Against the FY27 guidance from the May 2026 call — revenue of ₹2,200-2,400 Cr and EBITDA margins of 12-14% — this quarter's 3.39% margin is a sharp miss, and the ₹519.88 Cr Q1 run-rate needs to keep accelerating to reach the guided revenue band; the ₹1,400 Cr FY27 Blends target (within Specialty Ingredients) can't be verified from this filing's segment cuts. Two corporate developments this quarter: the Company completed its open offer for Vinpai S.A. minority shareholders on July 6, 2026, lifting its stake to 95.41% from 83.82% for ₹19.46 Cr; and the Board held the 33rd AGM and filed the FY26 BRSR report alongside these results. Management separately noted a second fire (Dahej Diphenol unit, May 23, 2026) is expected to be fully insurance-covered with no residual loss (Note 9) — worth checking given the ₹10.88 Cr shortfall just booked on the earlier Brazil claim. This sets up a Q2 FY27 where the key questions are whether Aroma's revenue growth converts to segment profit and whether the EBITDA margin starts closing the gap to the 12-14% guided range.